Aquestive Therapeutics, Inc. (AQST) 주식 분석

회사 개요

Aquestive Therapeutics, Inc. operates as a pharmaceutical entity within the United States and international markets, specializing in the development and commercialization of novel drug formulations designed for specific therapeutic indications. The company functions within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche medical treatments rather than mass-market consumer pharmaceuticals. At present, the firm employs a workforce of 147 individuals and holds a market capitalization of $508.93M, reflecting its valuation in the public equity markets. The company's annual revenue for the trailing twelve months stands at $44.55M, indicating a relatively small-scale operation compared to major pharmaceutical giants. These financial figures suggest that Aquestive is a mid-to-small cap biopharmaceutical company that relies on its proprietary product pipeline, such as Libervant and Suboxone, to generate revenue while navigating the high-cost environment of drug development and regulatory approval.

재무 건전성

The company reported a revenue of $44.55M over the trailing twelve months, yet it recorded a net income of $-83,784,000, revealing a significant operational loss that highlights a cost structure where expenses substantially exceed current sales. This gap between revenue and net income indicates that the company is currently in an investment phase typical of early-stage biotech firms, where research, development, and administrative costs consume the majority of cash flow before profitability is achieved. The EBITDA figure stands at $-70,477,000, further confirming that the business has not yet reached operational profitability despite generating positive sales. Free cash flow for the period was $-29,235,376, which signifies that the company is burning cash to fund its operations and growth initiatives, limiting its immediate financial flexibility for large-scale acquisitions or aggressive expansion without external capital. In terms of profitability margins, the gross margin is 58.3%, showing that the core production costs are well-controlled relative to sales, whereas the operating margin is -221.6% and the profit margin is -188.1%, indicating that general and administrative expenses are currently driving the company into deep negative territory. The balance sheet shows a cash position of $121.17M against total debt of $42.48M, suggesting the company holds significantly more liquid assets than liabilities, though the debt-to-equity ratio is listed as N/A due to the nature of its equity structure. The current ratio is 3.13, which indicates a strong ability to meet short-term obligations with current assets, providing a buffer against liquidity crises. Return on Equity is N/A, while Return on Assets is -33.9%, revealing that for every dollar of assets employed, the company generates a loss, a metric that reflects the current phase of the business rather than long-term management inefficiency.

밸류에이션 평가

The trailing P/E ratio is N/A because the company is unprofitable, while the forward P/E is listed at -7.19, a negative metric that prevents standard valuation comparisons but signals that the market does not expect immediate earnings turnaround. The price-to-book ratio is -15.11, which indicates that the market is valuing the company based on intangible assets and potential future cash flows rather than tangible book value, a common scenario for biotechnology firms with significant intellectual property portfolios. The price-to-sales ratio is 11.43, suggesting that investors are willing to pay a premium of over 11 times revenue for the company's future growth potential, while the EV/EBITDA stands at -6.11, further emphasizing that traditional multiple-based valuation is not applicable until the company generates positive earnings. The stock has traded within a 52-week range with a high of $7.55 and a low of $2.12, meaning the current price sits somewhere within this volatile band, reflecting the speculative nature of the investment. The beta value is 1.53, which indicates that the stock price is expected to be 53% more volatile than the broader market, exposing investors to higher risk during market downturns.

Growth & Income

The revenue growth year-over-year is 9.7%, demonstrating a healthy expansion in sales, whereas earnings growth is N/A due to the company's continued net losses, implying that top-line growth is not yet translating into bottom-line profitability. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all of its earnings to reinvest into research and development rather than distributing cash to shareholders. The absence of a dividend policy is consistent with the capital allocation strategy of growth-oriented biopharmaceutical companies that prioritize funding their pipeline over returning capital to investors. Overall, the growth and income profile of Aquestive Therapeutics is characterized by positive sales momentum supported by a lack of current profitability and no dividend distribution, positioning the stock as a high-risk, high-potential growth play dependent on the successful commercialization of its drug portfolio.